TheraRadar
← Back
Data updated: Jun 28, 2026

BIOCODEX SA

Pharma
GastroenterologyNeurology Execution: Fair

BIOCODEX SA is a pharmaceutical company focused on Gastroenterology, Neurology. Key products include DIACOMIT.

2018
Since
1
Drugs
-
Trials
0
New Drugs (2yr)
Modality:
1 Small Molecules

FDA Novel Drug Designations

(2018)
1 Novel 1 Orphan 1 Priority Review
See 1 novel approval →
2018 DIACOMIT (STIRIPENTOL) Orphan · Priority Review

BIOCODEX SA at a Glance

  • Fast trial execution (17 months median completion)

BIOCODEX SA's Key Drugs

BIOCODEX SA's core commercial portfolio centers on DIACOMIT, spanning Gastroenterology and Neurology — its most strategically important drugs approved in the last 15 years.

DIACOMIT
CNS
Approved 2018

BIOCODEX SA's Recent FDA Approvals

New NDA/BLA approvals for BIOCODEX SA over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

BIOCODEX SA's Therapeutic Areas

BIOCODEX SA's approved drugs and pipeline span 2 therapeutic areas, led by Gastroenterology and Neurology, across 0 biologic and 1 small-molecule drug. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Gastroenterology 80%
0 drugs Phase 3: 1
Neurology 20%
0 drugs Phase 1: 1

BIOCODEX SA's Top Competitors

BIOCODEX SA's closest competitors by therapeutic-area and drug-target overlap include Bristol-Myers Squibb, VALIDUS PHARMS, and EMD SERONO. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.

Bristol-Myers Squibb big-pharma
Gastroenterology, Neurology
VALIDUS PHARMS specialty
Gastroenterology, Neurology
EMD SERONO biotech
Neurology, Gastroenterology
WARNER CHILCOTT big-pharma
Gastroenterology, Neurology
CURIUM big-pharma
Gastroenterology, Neurology

BIOCODEX SA Pipeline Snapshot

BIOCODEX SA has 2 active clinical programs from ClinicalTrials.gov — 1 Phase 3, 0 Phase 2 and 1 Phase 1.

1
Phase 3
0
Phase 2
1
Phase 1

Phase 3 Readout Calendar Pro

2 Phase 3 trials with confidence-graded primary completion dates.

Full calendar →
Q4 2026
Saccharomyces Boulardii 250 MG
IBS (Irritable Bowel Syndrome)
Estimated · aging NCT07168434
Q3 2030
Stiripentol Oral Capsule
Primary Hyperoxaluria Type 1
Estimated · stale NCT06465472

Anchored on CT.gov primary completion date. Topline announcements typically precede this by 3–9 months. Confidence labels combine date type (ACTUAL/ESTIMATED) with last-update freshness.

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • • DIACOMIT leads revenue
  • • Drug-level revenue analysis

Trial Catalysts

  • • Gastroenterology pipeline focus
  • • 2 Phase 3 readouts tracked
View readout calendar →

Patent Risk

  • • Patent expiration timeline
  • • Revenue at risk analysis

Compare Companies

  • • Side-by-side pipeline analysis
  • • Revenue & market share comparison

Execution Intelligence

  • • Phase 3: 1/3 completed
  • • Speed: 17 months avg
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling

How We Calculate These Metrics

Execution Quality Score

Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.

What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.

  • Excellent (80%+): Top-tier execution, most trials reach planned endpoints
  • Good (60-79%): Strong execution with occasional early terminations
  • Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
  • Needs Improvement (under 40%): High termination rates, execution challenges